Literature DB >> 28631271

Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report.

Willemien S Kalteren1, Marco W J Schreurs2, Annelies Jorritsma-Smit3, Daan J Touw3, Jan Willem de Jong4, Petra G M A Zweers5, Fransje E Reesink1,6.   

Abstract

Entities:  

Keywords:  adverse drug reactions; neurology; respiratory medicine

Mesh：

Substances：

Year:  2017        PMID： 28631271      PMCID： PMC5595933          DOI： 10.1111/bcp.13338

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

Review 1.  A systematic review of drug-induced subacute cutaneous lupus erythematosus.

Authors:  G C Lowe; G Lowe; C L Henderson; R H Grau; C B Hansen; R D Sontheimer
Journal:  Br J Dermatol       Date:  2011-02-17       Impact factor: 9.302

2.  Trace level analysis of leached Protein A in bioprocess samples without interference from the large excess of rhMAb IgG.

Authors:  Judith Zhu-Shimoni; Feny Gunawan; Anne Thomas; Martin Vanderlaan; John Stults
Journal:  J Immunol Methods       Date:  2008-11-27       Impact factor: 2.303

Review 3.  Asthma.

Authors:  Christopher H Fanta
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

4.  Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer.

Authors:  Aaron I Loochtan; Myles S Nickolich; Lisa D Hobson-Webb
Journal:  Muscle Nerve       Date:  2015-05-14       Impact factor: 3.217

5.  Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report.

Authors:  Willemien S Kalteren; Marco W J Schreurs; Annelies Jorritsma-Smit; Daan J Touw; Jan Willem de Jong; Petra G M A Zweers; Fransje E Reesink
Journal:  Br J Clin Pharmacol       Date:  2017-06-19       Impact factor: 4.335

Review 6.  Effects of omalizumab on markers of inflammation in patients with allergic asthma.

Authors:  S Holgate; N Smith; M Massanari; P Jimenez
Journal:  Allergy       Date:  2009-10-15       Impact factor: 13.146

7.  Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.

Authors:  Elena Cortés-Vicente; Eduard Gallardo; María Ángeles Martínez; Jordi Díaz-Manera; Luis Querol; Ricard Rojas-García; Isabel Illa
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302
  7 in total
  2 in total

1.  Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report.

Authors:  Willemien S Kalteren; Marco W J Schreurs; Annelies Jorritsma-Smit; Daan J Touw; Jan Willem de Jong; Petra G M A Zweers; Fransje E Reesink
Journal:  Br J Clin Pharmacol       Date:  2017-06-19       Impact factor: 4.335

2.  Effects of omalizumab therapy on peripheral nerve functions: short observational study.

Authors:  Goknur Ozaydın Yavuz; Abdullah Yılgör; Ibrahim Halil Yavuz; Aysel Milanlıoğlu; Vedat Çilingir; Aydın Çağaç; Murat Ozturk; Serap Gunes Bilgili
Journal:  Postepy Dermatol Alergol       Date:  2018-04-03       Impact factor: 1.837
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.